Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
56 results about "Neurogenic pain" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neurogenic pain arises from, or is caused by, the nervous system. The term is a catch-all phrase for pain that occurs because of central or peripheral nervous system dysfunction.
Benzamide derivative or salt thereof
InactiveUS20070167444A1Strong inhibitory activityBiocideNervous disorderNeurogenic painOveractive bladder
There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).
Owner:ASTELLAS PHARMA INC
Therapeutic agent for pain disease
Disclosed is an analgesic agent for a non-inflammatory pain disease, which comprises a sialic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The sialic acid which is an active ingredient for the agent has an analgesic effect on a disease model animal of neurogenic pain which is a non-inflammatory pain. Therefore, the analgesic agent is useful as a pharmaceutical agent for the treatment of a non-inflammatory pain disease such as a neurogenic pain disease, e.g. trigeminal neuralgia, postherpetic neuralgia, entrapment neuropathy, complex regional pain syndrome, diabetic neuropathy, traumatic neuropathy, phantom limb pain, central pain after spinal cord injury or stroke, and neuropathy caused by pharmacotherapy or radiation therapy, or the like.
Owner:NIPPON ZOKI PHARM CO LTD
Heterocyclic compound
ActiveUS10323026B2Superior MAGL inhibitory actionAgent for prophylaxis and treatmentNervous disorderOrganic chemistryHuntingtons choreaBrain traumas
The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as defined in the specification, or a salt thereof.
Owner:TAKEDA PHARMA CO LTD
Novel phenylacetate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for prevention or treatment of diseases induced by activation of t-type calcium ion channel containing the same as an active ingredient
ActiveUS20100056545A1Inhibition is effectiveEffective activityBiocideNervous disorderBiological activationBULK ACTIVE INGREDIENT
Disclosed herein are a new phenylacetate derivative represented by Chemical Formula 1 or pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for prevention or treatment of diseases induced by the activation of T-type calcium ion channels containing the same. The composition containing the phenylacetate derivative according to the present invention effectively inhibits the activation of T-type calcium ion channels and may be useful in the prevention or treatment of diseases such as hypertension, cancer, epilepsy, and neurogenic pains induced by the activation of T-type calcium ion channels.wherein, X, R1, and R3 are as defined herein.
Owner:KOREA INST OF SCI & TECH
Heterocyclic compound
ActiveUS20170283406A1Superior MAGL inhibitory actionAgent for prophylaxis and treatmentNervous disorderOrganic chemistryHuntingtons choreaBrain traumas
The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as defined in the specification, or a salt thereof.
Owner:TAKEDA PHARMA CO LTD
Interconnected medicine precursor of gabapentin and pregabalin and its medicinal use
The present invention relates to the interconnected medicine precursor of gabapentin and pregabalin and its non-toxic pharmaceutically acceptable salt and their use in preparing medicines for treating epilepsy, neurogenic pain and / or anxiety neurosis.
Owner:INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Application of dragon's blood and flavonoid chemical component thereof in serving as antagonist of capsaicin receptor TRPV1 (transient receptor potential vanilloid 1)
InactiveCN102406787AStrong activation inhibitionEnhance pharmacological effectsNervous disorderAntipyreticDiseaseCochinchinenin
The invention relates to applications of dragon's blood and a flavonoid chemical component thereof in serving as an antagonist of a capsaicin receptor TRPV1 (transient receptor potential vanilloid 1) and in preparing a medicament for treating diseases related to TRPV1 receptors, wherein the flavonoid chemical component is cochinchinenin A or a mixture of at least two of cochinchinenin A, cochinchinenin B and loureirin B. The invention also relates to a medicinal composition comprising the dragon's blood and and the flavonoid chemical component thereof. Independent component of the dragon's blood or the cochinchinenin A, or a combination of every two of the cochinchinenin A, the cochinchinenin B and the loureirin B, or a combination comprising the cochinchinenin A, the cochinchinenin B and the loureirin B has strong capsaicin receptor TRPV1 activation inhibition effect and excellent pharmacological action based on the inhibition effect, so that the dragon's blood or the flavonoid chemical component thereof serving as an active component can be used for preparing medicaments for treating or preventing TRPV1 related diseases, such as nociceptive pains, neurogenic pains, cancer pains, headache, urinary bladder functional disorder, inflammation and the like.
Owner:SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
ActiveUS20160256395A1Minimize degradationImprove tolerancePowder deliveryOrganic active ingredientsDiseaseSucrose
The present invention relates to compressed tablets for peroral delivery of the cannabinoid Δ9-tetrahydrocannabinol (THC). More particularly, the invention provides a compressed tablet having a tablet weight of 25-1000 mg, said tablet being composed of: compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment 30-90 wt % of a granulate; 10-70 wt % of lactose; and 0-30 wt % of other tablet excipients; wherein the granulate contains: a. 2-5 wt % of Δ9-tetrahydrocannabinol; b. 2-20 wt % of sucrose fatty acid mono-ester; c. 50-96 wt % of lactose; d. 0.05-0.6 wt % of antioxidant; and e. 0-25 wt % of other granulate excipients. The compressed tablets according to the invention can conveniently be used in the treatment of spasticity and pain caused by multiple sclerosis, neurophatic pain, chronic pain, behavioral disturbance by Alzheimer's disease, stroke, spinal cord injury, peripheral neuropathy, neurogenic pain, nociceptive pain and nausea. The invention further provides a method for the manufacture of the compressed tablets.
Owner:ECHO PHARM BV (NL)
Heterocyclic compound
ActiveUS20200255439A1Superior MAGL inhibitory actionAgent for prophylaxis and treatmentOrganic active ingredientsNervous disorderHuntingtons choreaAmytrophic lateral sclerosis
The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as defined in the description, or a salt thereof.
Owner:TAKEDA PHARMA CO LTD
GLP-1 acceptor agonists used for treating pains
The invention relates to glucagon-like peptide-1 (GLP-1) acceptor agonists (comprising: macromolecular agonists, such as GLP-1 and derivatives thereof, and exendins and derivatives thereof; and micromolecular agonists, such as geniposides) used for treating diseases, such as pains, especially chronic pains, comprising neuropathic pains, cancer pains, diabetic pains, immune inflammation pains, pains in back and loin, and the like which can be treated through activating a central nervous system comprising a spinal cord GLP-1 acceptor.
Owner:王永祥
Application of 7-O-beta-D-acetylation sugar-coumarin compounds in treating chronic neuropathic pains
The invention relates to application of 7-O-beta-D-acetylation sugar-coumarin compounds in treating chronic neuropathic pains. The 7-O-beta-D-acetylation sugar-coumarin compounds comprise a pharmaceutically acceptable salt, ester or a solvate thereof, and the application relates to the application of the salt, the ester or the solvate in preparing medicaments for treating the chronic neuropathic pains, wherein a glycosyl part is arbitrary pyranose or furanose, the hydroxy of which is totally acetylated; a representative compound is 7-O-beta-D-acetylation glucose-coumarin; and the structural formula is disclosed in the specification. On a classical sciatic nerve chronic compression injury (CCI) model, through single intragastric administration and continuous intragastric administration for 7 days, the compound shows definite treatment effect of resisting nervous pains. At a dose point appointed by an experiment, the compound can obviously improve the mechanical stimulus pain threshold, the nervous pain resistant efficacy is equivalent to that of Gabapentin which is a contrast medicament, and the duration is superior to that of the Gabapentin. Proved by research results, the compound can be used for treating the chronic neuropathic pains.
Owner:YUNNAN UNIV
Heterocyclic compound
ActiveUS10610520B2Superior MAGL inhibitory actionAgent for prophylaxis and treatmentOrganic active ingredientsNervous disorderHuntingtons choreaCarcinomatoses
Owner:TAKEDA PHARMA CO LTD
Heterocyclic compound
ActiveUS10106556B2Superior MAGL inhibitory actionAgent for prophylaxis and treatmentOrganic active ingredientsNervous disorderHuntingtons choreaEpilepsy
Owner:TAKEDA PHARMA CO LTD
Agent for treating and/or preventing of neuropathic pain
InactiveCN101171029AReduce the burden onEliminate side effectsNervous disorderPeptide/protein ingredientsSerum igeSerum Calcium Level
To provide a pharmaceutical which has an action effective for the treatment of various neurogenic pains and shows a low toxicity. A therapeutic agent and / or prophylactic agent for a neurogenic pain comprising a calcitonin (particularly elcatonin) as an active ingredient, the calcitonin being administered continuously in such an amount that does not vary the serum calcium level; and use of a calcitonin (particularly elcatonin) for the preparation of a therapeutic agent and / or prophylactic agent for a neurogenic pain.
Owner:ASAHI KASEI PHARMA
Heterocyclic compound
ActiveUS20180079756A1Superior MAGL inhibitory actionAgent for prophylaxis and treatmentOrganic active ingredientsNervous disorderHuntingtons choreaBrain traumas
The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates a compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof.
Owner:TAKEDA PHARMACEUTICALS CO LTD
Non-traumatic model for neurogenic pain
A method for producing a non-human mammalian model for neurogenic pain is provided, which includes altering a peripheral nerve of a non-human mammal by non-surgically placing a gel substance into the fascial tunnel through which the peripheral nerve passes. The placement of the gel substance leads to one or more pain behaviors thereby producing the pain model. Also provided is a non-human mammalian model for neurogenic pain so produced. Further provided is a method for screening a treatment or a therapeutic agent for efficacy in treating neurogenic pain as well as a method for screening an analgesic agent for analgesic effect in neurogenic pain.
Owner:NEURODIGM LLC A COLORADO CORP
Pyrrolidine analogue for preventing neurogenic pain and method for production thereof
InactiveUS7968733B2Readily and massively producedFacilitate functioningNervous disorderOrganic chemistryPyrrolidineNeurogenic pain
Owner:HAMAMATSU PHOTONICS KK
Application of sinomenine in the preparation of drugs for the treatment of chronic pain accompanied by depressive behavior
ActiveCN104257658BRelieve painImprove depression-like behaviorOrganic active ingredientsNervous disorderSedative EffectsTolerability
The invention relates to a new medical application of sinomenine. The invention provides the application of sinomenine as the sole active ingredient in the preparation of a medicine for treating chronic pain accompanied by depression behavior. The present invention uses a rat model of sciatic nerve compression injury, which manifests as chronic neurogenic pain and induces depressive behavior, and confirms that sinomenine has a good analgesic effect on chronic pain, and can improve its depressive-like behavior without tolerance Adverse reactions such as acceptability and sedative effect.
Owner:苏州康纯医药科技有限公司
Non-traumatic model for neurogenic pain
Methods for producing nondestructive nerve alterations and / or compressions in animals are provided. The animals provide a model of persistent neurogenic and neuropathic pain in humans. Also provided is a method for screening agents for activity in the treatment of persistent neuropathic pain, as well as methods for use in developing agents for treatment of neuropathic pain. Also provided are methods for detecting and monitoring physiologic changes in persistent pain.
Owner:NEURODIGM LLC A COLORADO CORP
Ureide derivative and pharmaceutical application thereof
InactiveUS20100234395A1Good analgesic effectPrevention and therapyBiocideNervous disorderUracilBULK ACTIVE INGREDIENT
Discloses is a pharmaceutical agent comprising an ureide derivative represented by the formula: or a pharmaceutically acceptable salt thereof as an active ingredient. The ureide derivative or the pharmaceutically acceptable salt thereof is useful for the relief of a pain or the treatment or prevention of neurogenic pain.
Owner:TORAY IND INC
Method of attenuating neurogenic pain
Owner:SESSIONS PHARMA INC
Therapeutic Agent for Sensory Abnormality
InactiveUS20090069442A1Avoid symptomsImprove the quality of lifeBiocideSenses disorderMethyl groupChronic intractable pain
The present invention provides therapeutic agents for sensory disorders represented by the following formula (1):[wherein R1, R2, and R3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group].The cyclohexenone long chain alcohol of the present invention improves hyperalgesia or hypoalgesia, and thus is useful as therapeutic agents for sensory disorders. Sensory disorders that can be prevented or treated by the present invention include chronic intractable pain, neurogenic pain, reduction of pain threshold caused by nerve injuries, hypesthesia or hyperesthesia caused by diabetes and nerve injuries, and the like.
Owner:MEIJI CO LTD
Inhibitors of C-FMS kinase
The invention relates to compounds of Formula I: wherein Z, X, J, R<2> and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.
Owner:JANSSEN PHARMA NV
Heterocyclic compound
ActiveUS20190125728A1Superior MAGL inhibitory actionAgent for prophylaxis and treatmentOrganic active ingredientsNervous disorderHuntingtons choreaBrain traumas
The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as defined in the specification, or a salt thereof.
Owner:TAKEDA PHARMA CO LTD
Novel therapeutic agent derived from marine organism
InactiveUS20090269415A1Improve securityNervous disorderOrganic chemistryViscous liquidCranial nerves
There is provided a nerve repairing agent, anti-ulcer agent or the like comprising an extract from a marine organism selected from organisms belonging to the class Holothuroidea, the phylum Porifera and the order Actiniaria or a material removed from a viscus of the organism. The extract has the following properties (1) to (4): (1) it is a almost colorless, transparent and viscous liquid having a slight fishy smell, or a almost white powder having a slight fishy smell which, when dissolved in water, is almost colorless and viscous; (2) a solution prepared by dissolving the liquid or powder in water shows the maximum absorbance at a wavelength of 264±10 nm; (3) a solution prepared by dissolving the liquid or powder in water shows an acidic pH value; and (4) it has at least one effect selected from a cranial nerve repairing effect, a nerve-growing effect, an insulin-releasing effect, an immunopotentiating effect, a noxious pain preventive effect, a neurogenic pain preventive effect, a diabetic sensory neuropathy ameliorating effect and an ulcer preventive effect.
Owner:IMEX JAPAN
Use of parapheny for maldehyde-O-beta-D-allose pyranoside for treating neurogenic pain
The present invention relates to the use of the compound of helicid, or its pharmaceutically acceptable salts, esters or solvates, for the manufacture of medicaments in treating neuropathic pain.
Owner:KUNMING BAKER NORTON PHARMA
Application of 3-carbethoxy phenyl-beta-D-glucoside in treating chronic neuropathic pains
The invention relates to 3-carbethoxy phenyl-beta-D-glucoside, or a pharmaceutically acceptable salt, ester or solvate thereof and application in preparing medicaments for treating neuropathic pains, wherein a glycosyl part is arbitrary pyranose or furanose; and a representative compound is 3-carbethoxy phenyl-beta-D-acylated xyloside the structural formula of which is disclosed in the specification. On a classical sciatic nerve chronic compression injury (CCI) model, through single intragastric administration and continuous intragastric administration for 7 days, the compound shows definite treatment effect on resisting nervous pains. At a dose point appointed by an experiment, the compound can obviously improve the mechanical stimulus pain threshold, the nervous pain resistant efficacy is equivalent to that of Gabapentin which is a contrast medicament, and the duration is superior to that of the Gabapentin. Proved by research results, the compound can be used for treating the chronic neuropathic pains.
Owner:YUNNAN UNIV
Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
ActiveUS9616025B2Minimize degradationImprove tolerancePowder deliveryOrganic active ingredientsDiseaseOral treatment
Owner:ECHO PHARM BV (NL)
Method for relieving neurogenic pain
Owner:NOVA NEURA
Medicines for treatment and prevention of neurogenic pain
A medicament for therapeutic and / or prophylactic treatment of neuropathic pain, which comprises a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:wherein R1 represents a hydrogen atom or a hydroxyl group; R2 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms; R3 represents a phenyl group which may have 1 to 3 atoms or substituents selected from the group consisting of a halogen atom, a hydroxyl group, an alkyl group having 1 to 3 carbon atoms, and an alkoxyl group having 1 to 3 carbon atoms, or represents —NH—R4 wherein R4 represents a phenyl group which may have 1 to 3 atoms or substituents selected from the group consisting of a halogen atom, a hydroxyl group, an alkyl group having 1 to 3 carbon atoms, and an alkoxyl group having 1 to 3 carbon atoms or hydrogen atom, and n represents 0 or 1.
Owner:HAMILTON PHARMA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com